xFOREST Therapeutics (Headquartered in Kamigyo-ku, Kyoto, Japan; Representative Director, President & CEO: Kaoru Richard Komatsu; hereinafter “xFOREST”) has been selected for 「すごいベンチャー100」2026 (Sugoi Venture 100), the annual feature by Toyo Keizai that highlights 100 promising startups in Japan.
The feature was published on Toyo Keizai Online on October 23, 2026. It also appears in the print edition of Weekly Toyo Keizai, the October 31 / November 7 combined issue, on sale October 26, 2026.
About xFOREST Therapeutics
xFOREST Therapeutics Co., Ltd. is a Kyoto-based RNA-targeted small molecule company. Building on its proprietary RNA structure analysis technology, xFOREST discovers selective small molecules for RNA targets that protein-first discovery cannot reach, and advances them into drug programs with partners.